Back to results
US 2020/0400689 A1Published application
Methods of treating based on site-specific tau phosphorylation
AssigneeWashington University
InventorsNicolas Barthelemy, Randall Bateman
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
Claims26
A method for treating a subject in need thereof, the method comprising
- (a) providing an isolated tau sample obtained from the subject and measuring, in the isolated tau sample, tau phosphorylation at T205 and T181, at T205 and T217, or at T205, T181, and T217;
- and
- (b) administering to the subject a pharmaceutical composition to decrease or stabilize the amount of the measured tau phosphorylation in step (a);
- wherein the isolated tau sample obtained from the subject contains:
- (i) tau phosphorylation at T181 that is about 1.5σ or above and/or tau phosphorylation at T217 that is about 1.5σ or above, and tau phosphorylation at T205 that is below about 1.5σ, or
- (ii) tau phosphorylation at T181 that is about 1.5σ or above and/or tau phosphorylation at T217 that is about 1.5σ or above, and tau phosphorylation at T205 that is about 1.5σ or above,
- where σ is the standard deviation defined by the normal distribution of tau phosphorylation at the residue measured in a control population without brain amyloid plaques as measured by PET imaging and/or Aβ42/40 measurement in CSF.
4 more elements
Dependencies are inferred from the claim text.